Elicio Therapeutics announces $15 million registered direct offering of 4.38 million common shares to support ELI-002 7P
Elicio Therapeutics, Inc. is a clinical-stage biotechnology firm dedicated to creating a diverse array of innovative immunotherapies for the treatment of various cancers and other diseases. The company's primary experimental drug, ELI-002, is an AMP therapeutic vaccine specifically formulated to target KRAS-driven cancers. Its development portfolio also encompasses ELI-004, an AMP-modified CpG adjuvant that forms part of ELI-002; ELI-007, a lymph node-targeted AMP-peptide vaccine addressing mutant BRAF-driven cancers; and ELI-008, a multivalent lymph node-targeted AMP-peptide vaccine for cancers expressing mutant TP53. Furthermore, Elicio is advancing ELI-005, a vaccine candidate for preventing COVID-19, and ELI-011 for hematological malignancies. Another program, ELI-012, is an mKRAS TCR T cell AMP-lifier designed for combined use with mKRAS-targeted TCR T cell therapy against mKRAS-driven cancers. The company's operations are headquartered in Boston, Massachusetts.
| Metric | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2013 |
|---|---|---|---|---|---|---|---|---|
| Revenue | N/A | N/A | N/A | $28.31M | $2.88M | $1.49M | $4.03M | $6.58M |
| Cost of Revenue | $1.18M | $1.17M | $1.06M | $1.23M | $1.82M | $1.14M | $380.00K | $3.17M |
| Gross Profit | $-1.18M | $-1.17M | $-1.06M | $27.08M | $1.06M | $351.00K | $3.65M | $3.41M |
| Gross Margin | 0.00% | 0.00% | 0.00% | 95.64% | 36.88% | 23.60% | 90.57% | 51.78% |
| Operating Expenses | $43.81M | $34.58M | $22.68M | $66.39M | $56.34M | $38.94M | $17.99M | $3.81M |
| Operating Income | $-44.99M | $-35.74M | $-23.73M | $-39.31M | $-55.27M | $-38.59M | $-14.34M | $-397.80K |
| Operating Margin | 0.00% | 0.00% | 0.00% | -138.84% | -1919.20% | -2595.23% | -355.97% | -6.04% |
| Net Income | $-51.90M | $-35.20M | $-28.21M | $-26.40M | $-80.11M | $-40.66M | $-20.02M | $632.24K |
| Net Margin | 0.00% | 0.00% | 0.00% | -93.25% | -2781.49% | -2734.23% | -497.02% | 9.61% |
| EPS (Basic) | $-4.25 | $-6.96 | $-9.10 | $-19.32 | $-1.93 | $-1.50 | $-6.79 | $103.31 |
| EBITDA | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Stock Option Compensation Expense | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Price To Earnings Ratio | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Price To Sales Ratio | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Shares Outstanding | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Market Capitalization | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |